{"id":"https://openalex.org/W3174878740","doi":"https://doi.org/10.2337/dc20-2926","title":"Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA","display_name":"Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA","alternate_titles":[],"publication_year":2021,"publication_date":"2021-06-18","ids":{"openalex":"https://openalex.org/W3174878740","doi":"https://doi.org/10.2337/dc20-2926","mag":"3174878740","pmid":"https://pubmed.ncbi.nlm.nih.gov/34385345","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8385465"},"language":"en","primary_location":{"id":"doi:10.2337/dc20-2926","doi":"https://doi.org/10.2337/dc20-2926","is_oa":false,"landing_page_url":"https://doi.org/10.2337/dc20-2926","pdf_url":null,"source":{"id":"https://openalex.org/S49878492","display_name":"Diabetes Care","issn_l":"0149-5992","issn":["0149-5992","1935-5548"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Care","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3174878740"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.2337/figshare.14580984.v1","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087060030","display_name":"HoJin Shin","orcid":"https://orcid.org/0000-0002-2032-6134","observed_orcids":["https://orcid.org/0000-0002-2032-6134"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"HoJin Shin","raw_affiliation_strings":["Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA","Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0002-2032-6134","affiliations":[{"raw_affiliation_string":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA","institution_ids":["https://openalex.org/I136199984"]},{"raw_affiliation_string":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004416630","display_name":"Sebastian Schneewei\u00df","orcid":"https://orcid.org/0000-0003-2575-467X","observed_orcids":["https://orcid.org/0000-0003-2575-467X"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sebastian Schneeweiss","raw_affiliation_strings":["Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037322697","display_name":"Robert J. Glynn","orcid":"https://orcid.org/0000-0002-0697-8996","observed_orcids":["https://orcid.org/0000-0002-0697-8996"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert J. Glynn","raw_affiliation_strings":["Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044474781","display_name":"Elisabetta Patorno","orcid":"https://orcid.org/0000-0002-8809-9898","observed_orcids":["https://orcid.org/0000-0002-8809-9898"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Elisabetta Patorno","raw_affiliation_strings":["Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0002-8809-9898","affiliations":[{"raw_affiliation_string":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5087060030"],"corresponding_institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"],"apc_list":null,"apc_paid":null,"fwci":7.6524,"has_fulltext":false,"cited_by_count":82,"citation_normalized_percentile":{"value":0.98421745,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"44","issue":"8","first_page":"1774","last_page":"1782"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":1.0},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.9300000071525574},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9779999852180481},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9520000219345093},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.9779999852180481},{"id":"https://openalex.org/keywords/drug-use-trends","display_name":"drug use trends","score":0.6850000023841858},{"id":"https://openalex.org/keywords/cardiovascular-disease","display_name":"cardiovascular disease","score":0.9860000014305115},{"id":"https://openalex.org/keywords/medicare-beneficiaries","display_name":"Medicare beneficiaries","score":0.7200000286102295},{"id":"https://openalex.org/keywords/commercially-insured-patients","display_name":"commercially insured patients","score":0.7839999794960022},{"id":"https://openalex.org/keywords/socioeconomic-status","display_name":"socioeconomic status","score":0.7080000042915344},{"id":"https://openalex.org/keywords/treatment-initiation","display_name":"treatment initiation","score":0.3240000009536743}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9343609809875488},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7332528829574585},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.7102404236793518},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5872581005096436},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40359580516815186},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3706164062023163},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33726152777671814},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.33288049697875977}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D004364","descriptor_name":"Pharmaceutical Preparations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D005947","descriptor_name":"Glucose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006278","descriptor_name":"Medicare","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.2337/dc20-2926","doi":"https://doi.org/10.2337/dc20-2926","is_oa":false,"landing_page_url":"https://doi.org/10.2337/dc20-2926","pdf_url":null,"source":{"id":"https://openalex.org/S49878492","display_name":"Diabetes Care","issn_l":"0149-5992","issn":["0149-5992","1935-5548"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Care","raw_type":"journal-article"},{"id":"doi:10.2337/figshare.14580984.v1","doi":"https://doi.org/10.2337/figshare.14580984.v1","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.14580984.v1","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},{"id":"pmh:oai:pubmedcentral.nih.gov:8385465","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8385465/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Care","raw_type":"Text"},{"id":"pmid:34385345","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34385345","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes care","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.2337/figshare.14580984.v1","doi":"https://doi.org/10.2337/figshare.14580984.v1","is_oa":true,"landing_page_url":"https://doi.org/10.2337/figshare.14580984.v1","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[{"id":"https://openalex.org/G4581603693","display_name":"Novel Approaches to Monitor the Safety and Effectiveness of Newly Marketed Diabetes Medications in Older Adults Considering Frailty and Multimorbidity","funder_award_id":"K08AG055670","funder_id":"https://openalex.org/F4320337337","funder_display_name":"National Institute on Aging"}],"funders":[{"id":"https://openalex.org/F4320337337","display_name":"National Institute on Aging","ror":"https://ror.org/049v75w11"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W1809230663","https://openalex.org/W1946491572","https://openalex.org/W1991511572","https://openalex.org/W2033136851","https://openalex.org/W2041652400","https://openalex.org/W2066224491","https://openalex.org/W2145632027","https://openalex.org/W2146264128","https://openalex.org/W2158012927","https://openalex.org/W2171294019","https://openalex.org/W2182461571","https://openalex.org/W2205780732","https://openalex.org/W2264678375","https://openalex.org/W2462394222","https://openalex.org/W2503745853","https://openalex.org/W2626446274","https://openalex.org/W2705431294","https://openalex.org/W2738521922","https://openalex.org/W2741341764","https://openalex.org/W2767408736","https://openalex.org/W2768945936","https://openalex.org/W2806521060","https://openalex.org/W2900236147","https://openalex.org/W2900413769","https://openalex.org/W2908779316","https://openalex.org/W2911823242","https://openalex.org/W2912639857","https://openalex.org/W2955605212","https://openalex.org/W2992144798","https://openalex.org/W3093027350","https://openalex.org/W3115570060","https://openalex.org/W3212163080","https://openalex.org/W4256525495"],"related_works":["https://openalex.org/W3173964354","https://openalex.org/W4404324549","https://openalex.org/W4409942841","https://openalex.org/W4411036046","https://openalex.org/W4205376659","https://openalex.org/W3216214816","https://openalex.org/W2984115447","https://openalex.org/W2063226296","https://openalex.org/W4404302247","https://openalex.org/W4411477059"],"abstract_inverted_index":{"OBJECTIVE":[0],"We":[1],"evaluated":[2],"recent":[3],"use":[4,51,124,205],"trends":[5,49,150],"and":[6,30,59,105,117,133,136,145,165,173,208],"predictors":[7,72],"of":[8,52,73,102,107,125,157,184,206],"first-line":[9,53,74,81,201],"antidiabetes":[10,42,54,75,158],"treatment":[11,43,55,82],"in":[12,50],"patients":[13,35,189,219],"with":[14,36,148,160,182,190,220],"type":[15,37,84,191],"2":[16,38,85,128,192],"diabetes.":[17],"RESEARCH":[18],"DESIGN":[19],"AND":[20],"METHODS":[21],"Using":[22],"two":[23],"large":[24],"U.S.":[25],"health":[26],"insurance":[27],"databases":[28],"(Clinformatics":[29],"Medicare),":[31],"we":[32],"identified":[33],"adult":[34,188],"diabetes":[39],"who":[40],"initiated":[41,97],"from":[44,212],"2013":[45,213],"through":[46,214],"2019.":[47],"Quarterly":[48],"were":[56,68,112,167],"plotted":[57],"overall":[58],"stratified":[60],"by":[61,100,114,196],"cardiovascular":[62,162],"disease":[63],"(CVD).":[64],"Multinomial":[65],"logistic":[66],"regressions":[67],"fit":[69],"to":[70,170],"estimate":[71],"treatment,":[76],"using":[77],"metformin,":[78],"the":[79,88,94,198,204],"recommended":[80],"for":[83],"diabetes,":[86,193],"as":[87],"common":[89],"referent.":[90],"RESULTS":[91],"Metformin":[92],"was":[93,195,210],"most":[95,199],"frequently":[96],"medication,":[98],"used":[99,113],"80.6%":[101],"Medicare":[103],"beneficiaries":[104],"83.1%":[106],"commercially":[108],"insured":[109],"patients.":[110],"Sulfonylureas":[111],"8.7%":[115],"(Medicare)":[116],"4.7%":[118],"(commercial).":[119],"Both":[120],"populations":[121],"had":[122,174],"low":[123,211],"sodium\u2013glucose":[126],"cotransporter":[127],"inhibitors":[129],"(SGLT-2i,":[130],"0.8%":[131],"[Medicare]":[132,144],"1.7%":[134],"[commercial])":[135],"glucagon-like":[137],"peptide":[138],"1":[139],"receptor":[140],"agonists":[141],"(GLP-1Ra;":[142],"1.0%":[143],"3.5%":[146],"[commercial]),":[147],"increasing":[149],"over":[151],"time":[152],"(P":[153],"<":[154],"0.01).":[155],"Initiators":[156],"drugs":[159],"established":[161],"benefits":[163],"(SGLT-2i":[164],"GLP-1RA)":[166],"more":[168],"likely":[169],"be":[171],"younger":[172],"prevalent":[175],"CVD":[176],"or":[177],"higher":[178],"socioeconomic":[179],"status":[180],"compared":[181],"initiators":[183],"metformin.":[185],"CONCLUSIONS":[186],"Among":[187],"metformin":[194],"far":[197],"frequent":[200],"treatment.":[202],"While":[203],"SGLT-2i":[207],"GLP-1RA":[209],"2019,":[215],"it":[216],"increased":[217],"among":[218],"CVD.":[221]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3174878740","counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":24},{"year":2024,"cited_by_count":25},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2021-07-05T00:00:00"}
